We previously reported α-galactosyl ceramide (α-GC) and its analogs as strong activators of the anti-cancer effects of NKTs [51,52], and combining α-GC or its analog with IL-15 may be a promising add-on approach for anti-GD2 immunotherapy in high-risk NBL. The gene discussed is IL15; the disease is cancer.